Discover
Cognition Conversations
Cognition Conversations
Author: Cognition Conversations
Subscribed: 11Played: 48Subscribe
Share
© Cognition Conversations
Description
Cognition Therapeutics's “Conversations” series will feature virtual fireside chats with neuroscience experts who will discuss advances in the research and treatment of Alzheimer’s disease, dementia with Lewy bodies (DLB), and other age-related neurodegenerative conditions. All episodes are available to watch as video as cogrx.com/conversations.
10 Episodes
Reverse
Featuring:Brendan Kelley, MD (moderator), UT Southwestern Medical Center, Professor and Clinical Vice Chair in the Department of NeurologySamantha K. Holden, MD, MS, FAAN, University of Colorado School of Medicine, Associate Professor of Neurology, Vice Chair for Outpatient Neurology ServicesCarla Preyer, Salon Owner, Inspirational Speaker, Care Partner to her Husband, PatrickLinda Szypula Ed.D., Science Teacher, Care Partner to her Husband, JamesIndex:0:00 Introduction2:00 Caregiver Distress and Symptom Burden16:14 Measuring Meaningful Changes in a Clinical Trial22:09 Closing remarks
Featuring:
Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer
James E. Galvin, MD, MPH, University of Miami, Director of the Comprehensive Center for Brain Health, Miller School of Medicine
Lawrence S. Honig, MD, PhD, FAAN, Columbia University, Professor of Neurology, Irving Medical Center
David Shprecher, D.O., Banner Sun Health Research Institute, Movement Disorder Director, Banner Sun HealthClinical Associate Professor, University of Arizona
Index:
0:00 Introduction
0:45 Comparing Alzheimer’s disease and DLB
5:02 SHIMMER Design and Outcomes
10:22 Metrics for Success in a Signal-finding Study
Featuring:
Anthony Caggiano, M.D., Ph.D. (moderator)
Cognition Therapeutics, Chief Medical Officer
Mary Hamby, Ph.D. (moderator)
Cognition Therapeutics, Vice President of Research
Everard (Jort) Vijverberg, MD, PhD
Alzheimer Center at Amsterdam University Medical Center, Neurologist and CNS Trial Specialist
Tara Spires Jones, DPhil
University of Edinburgh, Personal Chair of Neurodegeneration and Deputy Director of the Centre for Discovery Brain Sciences
Index:
0:00 Introduction
3:49 Findings from SEQUEL
6:45 Clinical observations of CT1812 engagement
9:08 Proteomic evidence of CT1812 engagement
11:52 CT1812’s ongoing Phase 2 study
Featuring:
Anthony Caggiano, M.D., Ph.D. (moderator), Cognition Therapeutics, Chief Medical Officer
Willem de Haan, M.D., Ph.D., Alzheimer Center at Amsterdam University Medical Center, Neurologist and Senior Researcher
Philip Scheltens, M.D., EQT Life Sciences, Partner and Head of Dementia Fund, Former Director of the Alzheimer Center at Amsterdam University Medical Center
Index:
0:00 Introduction
0:44 Rationale for the SEQUEL Study Design
2:10 EEG in neurodegenerative diseases
4:33 Findings from SEQUEL
9:52 Key Takeaways
Featuring:
Anthony Caggiano, M.D., Ph.D., Chief Medical Officer, Cognition Therapeutics
C. Gustavo De Moraes, M.D., Ph.D. (moderator), Chief Medical Officer, Ora (CRO), and Associate Professor of Clinical Ophthalmology, Columbia University
Jeffrey S. Heier, M.D., Director of the Vitreoretinal Service & Retina Research, Ophthalmic Consultants of Boston
Peter K. Kaiser, M.D., Chaney Family Endowed Chair in Ophthalmology Research and Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine




